☆ 4.7 Letter

Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)

Get Full Text
Add to Collection

Journal

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
Volume 139, Issue 3, Pages 1059-1061

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2016.07.047

Keywords

-

Categories

Allergy Immunology

Funding

  1. Novartis Pharma GmbH
  2. Medixiline
  3. Index Venture Management Jersey Ltd
  4. Sanofi
  5. Nerre
  6. LORA Group
  7. Jenapharm
  8. Novartis
  9. Charite
  10. Bayer
  11. MarDi
  12. Dr. R. Pfleger
  13. Urtimed
  14. Klinikzentrum Bad Sulza
  15. GlaxoKline
  16. DDG
  17. ADF
  18. Universitat Munster
  19. Roche
  20. Arztekammer Berlin
  21. BVDD
  22. Mediengruppe Oberfranken
  23. Moxie GmbH
  24. Rahel-Hirsch-Stipend
  25. RefLab ApS
  26. Uriach
  27. Genentech
  28. Moxie

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.